Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum

Key facts

Sponsor

Technical University of Munich

Principal Investigator

Kilian Eyerich, MD, PhD

Technical University of Munich

Intervention

Secukinumab(drug)

Enrollment

8 enrolled

Eligibility

18-75 years · All sexes

Timeline

2016 – 2019

Study locations (1)

• Technical University of Munich, Munich, Germany

Collaborators

Novartis

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Classic pyoderma gangrenosum

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT06624670
  A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
  Boehringer Ingelheim
• RECRUITINGPHASE2NCT06563323
  Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
  Oregon Health and Science University

See all trials for Classic pyoderma gangrenosum →